Loss of autoinhibition of the plasma membrane Ca(2+) pump by substitution of aspartic 170 by asparagin. A ctivation of plasma membrane calcium ATPase 4 without disruption of the interaction between the catalytic core and the C-terminal regulatory domain.
The plasma membrane calcium ATPase (PMCA) actively transports Ca(2+) from the cytosol to the extra cellular space. The C-terminal segment of the PMCA functions as an inhibitory domain by interacting with the catalytic core. Ca(2+)-calmodulin binds to the C-terminal segment and stops inhibition. Here we showed that residue Asp(170), in the putative "A" domain of human PMCA isoform 4xb, plays a critical role in autoinhibition. In the absence of calmodulin a PMCA containing a site-specific mutation of D170N had 80% of the maximum activity of the calmodulin-activated PMCA and a similar high affinity for Ca(2+). The mutation did not change the activation of the PMCA by ATP. Deletion of the C-terminal segment further downstream of the calmodulin-binding site led to an additional increase in the maximal activity of the mutant, which suggests that the mutation did not affect the inhibition because of this portion of the C-terminal segment. The calmodulin-activated PMCA was more sensitive to vanadate inhibition than the autoinhibited enzyme. In contrast, inhibition of the D170N mutant required higher concentrations of vanadate and was not affected by calmodulin. Despite its higher basal activity, the mutant had an apparent affinity for calmodulin similar to that of the wild type enzyme, and its rate of proteolysis at the C-terminal segment was still calmodulin-dependent. Altogether these results suggest that activation by mutation D170N does not involve the displacement of the calmodulin-binding autoinhibitory domain from the catalytic core and may arise directly from changes in the accessibility to the calcium-binding residues of the pump.
Instituto de Química y Fisicoquímica Biológicas (IQUIFIB)-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1113 Ciudad de Buenos Aires, Argentina.
Luis M
LM
Bredeston
Hugo P
HP
Adamo
D000255:Adenosine Triphosphate / Q000494:pharmacology; D019943:Amino Acid Substitution; D001665:Binding Sites; D000252:Calcium-Transporting ATPases / Q000235:genetics / Q000502:physiology*; D002147:Calmodulin / Q000378:metabolism / Q000494:pharmacology; D020134:Catalytic Domain; D002462:Cell Membrane / Q000737:chemistry*; D003001:Cloning, Molecular; D025461:Feedback, Physiological / Q000235:genetics*; D006801:Humans; D007700:Kinetics; D008081:Liposomes; D009154:Mutation; D014638:Vanadates / Q000494:pharmacology
D002147:Calmodulin; D008081:Liposomes; D014638:Vanadates; D000255:Adenosine Triphosphate; D000252:Calcium-Transporting ATPases